Abstract
Retrospective analysis of serum samples from a group of hemophiliac patients who became infected with human immunodeficiency virus type 1 (HIV-1) between 1984 and 1985 has shown that, at variance with other HIV-1-infected patients, at the onset, or at least at a very early phase of HIV-1 infection, they constantly have elevated levels of antibodies against HIV-1-transactivating Tat protein and an absent or barely detectable p24 antigenemia. Anti-Tat antibodies in initial serum samples from hemophiliac patients were probably the consequence of the passive administration of immunoglobulins present in low- or intermediate-purity clotting factor concentrates prepared from HIV-1-infected blood. Furthermore, the analysis of serial serum samples obtained during the course of the disease, in which passively acquired anti-Tat antibodies were substituted by actively produced antibodies, demonstrated an inverse relationship between anti-Tat antibody and p24 anti-genemia levels throughout the observation period. These data seem to suggest that anti-Tat antibody may have some influence on the course of HIV-1 infection.
Full Text
The Full Text of this article is available as a PDF (171.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arya S. K., Gallo R. C. Three novel genes of human T-lymphotropic virus type III: immune reactivity of their products with sera from acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A. 1986 Apr;83(7):2209–2213. doi: 10.1073/pnas.83.7.2209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cullen B. R. Regulation of HIV-1 gene expression. FASEB J. 1991 Jul;5(10):2361–2368. doi: 10.1096/fasebj.5.10.1712325. [DOI] [PubMed] [Google Scholar]
- Ensoli B., Gendelman R., Markham P., Fiorelli V., Colombini S., Raffeld M., Cafaro A., Chang H. K., Brady J. N., Gallo R. C. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature. 1994 Oct 20;371(6499):674–680. doi: 10.1038/371674a0. [DOI] [PubMed] [Google Scholar]
- Franchini G., Robert-Guroff M., Aldovini A., Kan N. C., Wong-Staal F. Spectrum of natural antibodies against five HTLV-III antigens in infected individuals: correlation of antibody prevalence with clinical status. Blood. 1987 Feb;69(2):437–441. [PubMed] [Google Scholar]
- Krone W. J., Debouck C., Epstein L. G., Heutink P., Meloen R., Goudsmit J. Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo. J Med Virol. 1988 Nov;26(3):261–270. doi: 10.1002/jmv.1890260306. [DOI] [PubMed] [Google Scholar]
- Levy J. A. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev. 1993 Mar;57(1):183–289. doi: 10.1128/mr.57.1.183-289.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Morfini M., Rafanelli D., Filimberti E., Cinotti S., Piazza E., Longo G., Rossi Ferrini P. Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates. Thromb Res. 1989 Oct 15;56(2):169–178. doi: 10.1016/0049-3848(89)90159-x. [DOI] [PubMed] [Google Scholar]
- Peerlinck K., Goubau P., Coppens G., Desmyter J., Vermylen J. Is the apparent outbreak of hepatitis A in Belgian hemophiliacs due to a loss of previous passive immunity? Vox Sang. 1994;67 (Suppl 1):14–17. [PubMed] [Google Scholar]
- Reiss P., Lange J. M., de Ronde A., de Wolf F., Dekker J., Debouck C., Goudsmit J. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol. 1990 Mar;30(3):163–168. doi: 10.1002/jmv.1890300303. [DOI] [PubMed] [Google Scholar]
- Reiss P., de Wolf F., Kuiken C. L., de Ronde A., Dekker J., Boucher C. A., Debouck C., Lange J. M., Goudsmit J. Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals. J Acquir Immune Defic Syndr. 1991;4(2):165–172. [PubMed] [Google Scholar]
- Steinaa L., Sørensen A. M., Nielsen J. O., Hansen J. E. Antibody to HIV-1 Tat protein inhibits the replication of virus in culture. Arch Virol. 1994;139(3-4):263–271. doi: 10.1007/BF01310790. [DOI] [PubMed] [Google Scholar]
- Zauli G., La Placa M., Vignoli M., Re M. C., Gibellini D., Furlini G., Milani D., Marchisio M., Mazzoni M., Capitani S. An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently Tat-transfected cells and required for optimal HIV-1 LTR transactivating activity. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):306–316. [PubMed] [Google Scholar]